FEATURED

Active Surveillance and Watchful Waiting

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

Low-fat Diet and Breast Cancer

Data suggest that a low-fat diet with an increase in vegetable and fruit intake may lower the risk of all-cause mortality among women with breast cancer.

Adverse Effects of Sarcoma Treatment

Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.

FDA: Drug Prices, Cancer Treatment

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Overcoming Resistance to ALK Inhibition

The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.

Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Ask the Experts: Treating Sarcoma

Cancer Therapy Advisor interviewed 3 experts about how to best treat sarcoma.

Q&A: Personalizing Immunotherapy for RCC

In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.

Intratumoral IL-12 Electroporation for Melanoma

Intratumoral, or intralesional, therapies are injected directly into the tumor, but can have systemic effects such that some non-injected lesions demonstrate regression.

Monoclonal Antibodies as “Magic Bullets”

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer

Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.

The Adverse Effects of Sarcoma Treatment in Cancer Survivors

The Adverse Effects of Sarcoma Treatment in Cancer Survivors

Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.

Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Overcoming Resistance to ALK Inhibition in Lung Cancer

Overcoming Resistance to ALK Inhibition in Lung Cancer

The development of ALK inhibitors for non-small cell lung cancer is rapidly progressing, yet acquired treatment resistance remains a key issue for a majority of patients.

Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters